Literature DB >> 33799327

Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice.

Celine Jacobs1, Lore Lapeire1,2.   

Abstract

Soft tissue sarcomas are a group of rare mesenchymal tumors with more than 70 subtypes described. Treatment of these subtypes in an advanced setting is mainly according to a one-size-fits-all strategy indicating a high unmet need of new and more targeted therapeutic options in order to optimize survival. The introduction of advanced molecular techniques in cancer has led to better diagnostics and identification of new therapeutic targets, leading to more personalized treatment and improved prognosis for several cancer types. In sarcoma, a likewise evolution is seen, albeit at a slower pace. This manuscript describes how in the past years advanced molecular profiling in soft tissue sarcomas was able to identify specific and often pathognomonic aberrations, deferring standard sarcoma treatment in favor of more targeted treatment from an oncologist's point of view.

Entities:  

Keywords:  ALK; CDK4; KIT; MDM2; NR4A3; NTRK; PD-1; PDGFRA; molecular profiling; sarcoma

Year:  2021        PMID: 33799327      PMCID: PMC7999686          DOI: 10.3390/diagnostics11030512

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  64 in total

Review 1.  Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.

Authors:  Tarek Assi; Joseph Kattan; Elie Rassy; Hussein Nassereddine; Fadi Farhat; Charles Honore; Axel Le Cesne; Julien Adam; Olivier Mir
Journal:  Crit Rev Oncol Hematol       Date:  2020-06-18       Impact factor: 6.312

2.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

Authors:  David S Hong; Steven G DuBois; Shivaani Kummar; Anna F Farago; Catherine M Albert; Kristoffer S Rohrberg; Cornelis M van Tilburg; Ramamoorthy Nagasubramanian; Jordan D Berlin; Noah Federman; Leo Mascarenhas; Birgit Geoerger; Afshin Dowlati; Alberto S Pappo; Stefan Bielack; François Doz; Ray McDermott; Jyoti D Patel; Russell J Schilder; Makoto Tahara; Stefan M Pfister; Olaf Witt; Marc Ladanyi; Erin R Rudzinski; Shivani Nanda; Barrett H Childs; Theodore W Laetsch; David M Hyman; Alexander Drilon
Journal:  Lancet Oncol       Date:  2020-02-24       Impact factor: 41.316

Review 3.  Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives.

Authors:  Till-Martin Theilen; Jan Soerensen; Konrad Bochennek; Martina Becker; Dirk Schwabe; Udo Rolle; Thomas Klingebiel; Thomas Lehrnbecher
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

Review 4.  Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.

Authors:  Javier Martín-Broto; David S Moura; Brian A Van Tine
Journal:  Clin Cancer Res       Date:  2020-06-29       Impact factor: 12.531

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.

Authors:  Silvia Stacchiotti; Stefano Ferrari; Andres Redondo; Nadia Hindi; Emanuela Palmerini; Maria Angeles Vaz Salgado; Anna Maria Frezza; Paolo Giovanni Casali; Antonio Gutierrez; Antonio Lopez-Pousa; Giovanni Grignani; Antoine Italiano; Axel LeCesne; Sarah Dumont; Jean Yves Blay; Nicolas Penel; Daniel Bernabeu; Enrique de Alava; Marie Karanian; Carlo Morosi; Silvia Brich; Gian Paolo Dagrada; Viviana Vallacchi; Chiara Castelli; Monica Brenca; Dominga Racanelli; Roberta Maestro; Paola Collini; Josefina Cruz; Javier Martin-Broto
Journal:  Lancet Oncol       Date:  2019-07-19       Impact factor: 41.316

7.  Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.

Authors:  Han Hsi Wong; Helen Bentley; Venkata Ramesh Bulusu; Gloria Anyaegbu; James Watkins; Gail Horan; Helen Hatcher
Journal:  Anticancer Drugs       Date:  2020-11       Impact factor: 2.248

8.  Liposarcoma: molecular genetics and therapeutics.

Authors:  Rachel Conyers; Sophie Young; David M Thomas
Journal:  Sarcoma       Date:  2010-12-27

9.  Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Authors:  D S Hong; T M Bauer; J J Lee; A Dowlati; M S Brose; A F Farago; M Taylor; A T Shaw; S Montez; F Meric-Bernstam; S Smith; B B Tuch; K Ebata; S Cruickshank; M C Cox; H A Burris; R C Doebele
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

View more
  2 in total

1.  BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation.

Authors:  Ken Saijo; Hiroo Imai; Hiromichi Katayama; Fumiyoshi Fujishima; Kenichi Nakamura; Yuki Kasahara; Kota Ouchi; Keigo Komine; Hidekazu Shirota; Masanobu Takahashi; Chikashi Ishioka
Journal:  Case Rep Oncol       Date:  2022-08-30

2.  Molecular Classification of Soft Tissue and Bone Tumors.

Authors:  David Creytens
Journal:  Diagnostics (Basel)       Date:  2021-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.